Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DXC008 in Prostate Cancer and Other Solid Tumors
NCT06926283Phase 1Recruiting
- Sponsor
- Hangzhou DAC Biotech
- Start
- May 2025
- Primary completion
- Apr 2030
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of DXC008 in prostate cancer (PCa), solid tumor and Ewing sarcoma, sponsored by Hangzhou DAC Biotech. Primary endpoints: Dose Limiting Toxicities at 28 days and Adverse Events at 1 year. Started May 2025; status: recruiting.
02
Drugs
DXC008
03
Conditions
prostate cancer (PCa)solid tumorEwing sarcoma
Beyond the preview
Go deeper on NCT06926283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926283.